Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

Vera Therapeutics stock rocketed nearly 70% on Monday on upbeat data for a kidney-disease trial. Shares are tumbling Friday ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant ...

Relative to drug developers, medical device makers have outperformed amid the turmoil of the Trump administration's healthcare reforms.

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

The ASX biotech sector dipped slightly in value in May, but stocks such as Medadvisor and Dimerix recorded lusty gains.

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...